Curriculum
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025
P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain is a 3-part curriculum which examines the full spectrum of pain management options available to clinicians, including the safe and effective use of opioids. AMGA has partnered with Pri-Med’s P.A.C.T. Update: Practical Approaches to Comprehensive Treatment of Pain 2024-2025 curriculum to provide education to AMGA physicians and other AMGA health care providers engaged in prescribing and or treating patients with opioid analgesics. This program is intended for those involved with direct patient care, including all members of the healthcare team. This curriculum is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration (FDA).
You must complete all three parts in order to be considered a REMS FDA Blueprint Completer
Part 1 of this series, Assessing Pain and Initiating Non-Opioid Pain Management, focuses on improving clinicians’ ability to recognize, diagnose, and classify pain, while educating clinicians on nonpharmacologic and nonopioid pharmacologic treatment options.
Part 2, Reducing Risks with Opioid Use, focuses on improving clinicians’ ability to assess potential risk factors for abuse and opioid use disorder/addiction. Clinicians will also review best practices to reduce the risks associated with prescription of opioid analgesics, information about safe opioid prescribing, as well as safe storage and disposal.
Part 3, Approaches to Opioid Treatment and Counseling Patients, will focus on providing risk reduction strategies through integration of opioids into individualized pain management plans. Clinicians will learn counseling strategies, including counseling about the use of naloxone for opioid overdose and how to recognize opioid use disorder and act appropriately to treat or refer patients.
This curriculum is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies.
By participating in the curriculum, you are opting in to allow Pri-Med to provide AMGA with participation/completion of participants and results by aggregate for each AMGA Medical Organization.

CME Information
4.00 AMA PRA Category 1 Credits, 4.00 ABIM MOC or 4.29 AANP, 1.66 AANP Pharm
Release Date: 12/17/2024
Available for credit until 10/31/2025
Topics
- Cultural Competency & Humility - Implicit Bias
- Controlled Substances - Alabama
- Controlled Substances - Louisiana
- Controlled Substances - Michigan
- Controlled Substances - New Mexico
- Controlled Substances - New York
- Controlled Substances - Tennessee
- Controlled Substances - Vermont
- Controlled Substances - Drug Diversion, WV Board Approved
- Controlled Substances - Prescribing, WV Board Approved
- Controlled Substances - Prescribing - Kentucky Board Approved HB1
- Controlled Substances
- Controlled Substances - Drug Diversion
- Medical Ethics & Legal Issues
- Medical Ethics & Legal Issues - Patient Safety
- Medical Ethics & Legal Issues - Professional Responsibility
- Medical Ethics & Legal Issues - Risk Management
- Psychiatry & Behavioral Health - Addiction
- Psychiatry & Behavioral Health - Substance Abuse
- Psychiatry & Behavioral Health - Substance Use Disorder
- Controlled Substances - PDMP
- Controlled Substances - Schedule II/III
- MATE Act
- Opioids
- Opioids - Abuse
- Opioids - Addiction
- Opioids - Opioid Antagonists
- Opioids - Prescribing
- Pain Management
- Non-pharmacologic Pain Management & Implantable Devices
Learning Objectives
- Discuss the definitions and mechanisms of pain
- Identify risk factors and stratification for opioid-related aberrant behavior and opioid use disorder as part of the initial assessment
- Apply individualized recommendations for nonpharmacologic and non-opioid treatment options for patients in pain
- Review general characteristics of opioid analgesics including their intended use and risks
- Differentiate among tolerance, physical dependence, and manifestations of opioid use disorder
- Recognize best practices to reduce the risks associated with prescription of opioid analgesics, including safe storage and disposal
- Anticipate and manage adverse effects of opioid use including signs of opioid overdose and the use of naloxone
- Select approaches to safely initiate opioids for the treatment of acute pain and chronic pain
- Identify strategies for ongoing safe and effective use of opioids in patients with chronic pain, including titration, referral, and discontinuation, when appropriate
- Summarize counseling strategies for caregivers and patients on opioid therapy
- Act appropriately to evaluate, treat, or refer patients with opioid use disorder
Courses
4.00 CME/CE CREDITS
3 Courses
-
Interactive Learning
-
Interactive Learning
-
Interactive Learning
Faculty Disclosures

Charles E. Argoff, MD, FABPM
Vice Chair, Albany Medical College, Professor of Neurology and Urology

Oscar A. de Leon-Casasola, MD
Professor of Anesthesiology and Medicine, Senior Vice-Chair, School of Medicine and Biomedical Sciences, University of Buffalo School of Medicine

Katherine E. Galluzzi, DO, CMD, FACOFP
Professor and Chairperson, Department of Geriatrics, Philadelphia College of Osteopathic Medicine, Philadelphia, PA
Supported By
Opioid Analgesic REMS Program Companies
Education Partner
Miller Medical Communications, LLC